Current News
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
.jpg "Fusion Antibodies - Landscape (Trimmed)")
.png "MyHealthChecked PLC_Logo_2 Line_Colour_Red_RGB_AW (003)"){kind=logo}
